NEW YORK CITY — When data from clinical trials of JAK inhibitors in atopic dermatitis (AD), vitiligo, and other skin diseases are stratified by race, response rates appear to diverge, with both higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results